BOTHELL, WA--(Marketwire - Jan 6, 2012) - Marina Biotech, Inc. (
"This unique financing structure permits us to access funds as they are required in the near future," stated J. Michael French, President and Chief Executive Officer at Marina Biotech, Inc. "With what we believe is the most unique and broadest nucleic acid drug discovery platform in the industry, we want to ensure we have the necessary funds to continue to execute on our business strategy. In 2011, we established ourselves broadly across the oligonucleotide therapeutic space with two technology deals (an RNAi drug discovery partnership with The Debiopharm Group and a microRNA delivery license with Mirna Therapeutics) as well as two separate nucleic acid technologies in clinical development (liposomal delivery of a single-stranded DNA through a license with ProNAi Therapeutics and our own on-going START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508). We feel access to these funds will give us the necessary financial flexibility to continue to execute on our pre-clinical, clinical and partnering objectives."
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Contact Information:
Contact:
Marina Biotech, Inc.
Phil Ranker
Interim Chief Financial Officer
(425) 908-3615
pranker@marinabio.com